Balanced news tone
News Sentiment
CAMP sentiment intelligence
CAMP4 THERAPEUTICS CORPORATION news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
75/100 classification confidence.
directly relevant articles
high-authority source matches
-14.3% over one week, -10.2% over four weeks, trend inactive, and near fair-value range.
We Think Camp4 Therapeutics (NASDAQ:CAMP) Can Afford To Drive Business Growth
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
New CAMP4 hire receives 5,000-share stock option grant
CAMP4 Therapeutics (Nasdaq: CAMP) announced it granted a non-qualified stock option to a new employee to purchase 5,000 shares of common stock. This inducement award, granted under Nasdaq Listing Rule 5635(c)(4), has a 10-year term and an exercise price of $4.31, vesting over fou
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 May 2026 08:09
- Source
- Stock Titan
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 07 May 2026 07:00
- Source
- GlobeNewswire
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Three new CAMP4 hires get stock options at $4.59 a share
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Apr 2026 07:00
- Source
- Stock Titan
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Camp4 Therapeutics: Strong Cash Runway As CMP-002 Moves Toward Human Trials (NASDAQ:CAMP)
- Tone
- Positive 66/100
- Event
- Balance sheet
- Published
- 07 Mar 2026 08:00
- Source
- Seeking Alpha
CAMP4 Therapeutics Corporation (CAMP) Upgraded to Buy: Here's Why
- Tone
- Positive 84/100
- Event
- Analyst action
- Published
- 13 Jan 2026 08:00
- Source
- Market source
CAMP4 Announces an Oversubscribed Private Placement of up
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Sep 2025 07:00
- Source
- GlobeNewswire
Karyopharm Therapeutics (KPTI) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Apr 2025 03:10
- Source
- Stock Titan
CAMP4 Announces Pricing of Initial Public Offering
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Oct 2024 07:00
- Source
- GlobeNewswire
CAMP4 Therapeutics (CAMP) Stock Forecast and Price Target 2026 $CAMP
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 11 May 2024 15:51
- Source
- MarketBeat
CAMP4 Therapeutics (CAMP) Stock Price, News & Analysis $CAMP
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Jun 2015 14:04
- Source
- MarketBeat